This flu season hasn’t been as severe as others, but activity is starting to pick up, according to the Centers for Disease Control and Prevention. From September 30, 2018, to February 2, fewer people have sought outpatient care for the flu, and there have been fewer deaths than in recent years. Last year’s flu season was one of the worst in decades with about 80,000 deaths. (CNBC)

Bayer is stressing mild side effects from its prostate-cancer drug as it prepares to take on rivals. In late-stage trials with men with early stage prostate cancer, the drug’s only side effect was fatigue, making it more tolerable for elderly patients. Pfizer and Johnson & Johnson also have prostate-cancer drugs on the market. (Reuters)

The federal budget bill would give the Food and Drug Administration $269 million more than last year. The increase would be the largest boost for the agency since 2010. President Donald Trump signed the bill on Friday morning. (Endpoints)

The racial gap in cancer deaths has narrowed, but black people still die from cancer at higher rates than their white counterparts. Black men have a 19% higher rate of death from cancer than white men, compared with 47% higher nearly 30 years ago, according to the American Cancer Society. Black women have a 13% greater cancer-death rate than white women. Cancer deaths have declined overall, with the biggest drops in lung, prostate, and colon cancers. (Associated Press)

Egalet has bought a pain reliever and raised its price by 70%. Egalet acquired Iroko Pharmaceuticals this month and its pain and anti-inflammatory drug Zorvolex, then it boosted the price of the treatment to $650, up from $383 a year ago. (Axios)